Pfizer Rose To The COVID-19 Challenge And The Stars Aligned
Executive Summary
Pfizer moved aggressively and early as COVID-19 became a global health threat, and now the company, with its partner BioNTech, is the first to secure an emergency use authorization for a COVID vaccine from the US FDA.
You may also be interested in...
Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.
The 14 Billion Dose COVID-19 Manufacturing Challenge
Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.
‘Reckless’ State Campaigns Seek To Undermine Western COVID-19 Vaccines
China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.